Radiant Biotherapeutics, a biotechnology company, made new leadership appointments. Biotechnology executive Deborah Geraghty, Ph.D., was named President and Chief Executive Officer, entrepreneur and venture investor Stefan Larson, Ph.D., was appointed Chair of the Board of Directors, and physician-scientist Ingmar Bruns, M.D., Ph.D., joined as a Board Member.

These appointments follow the company’s $35 million Series A financing and build upon the recent progress by founding Chief Scientific Officer, Jo Hulme, Ph.D. 

Multabody, Radiant’s proprietary antibody platform, leverages avidity on intended targets while exploiting specificity to address multiple epitopes and different disease-modifying proteins. Antibodies developed using the Radiant platform are designed to deliver exceptional potency against solid tumors and blood cancers, immunological targets, and infectious disease pathogens.

Deborah Geraghty, Ph.D.

Geraghty is an accomplished life sciences executive with over 20 years of experience, having built a strong foundation of financial, operational, and strategic expertise throughout her career leading innovative biopharmaceutical companies. 

She most recently served as President and CEO of Anokion SA, a Phase 2 clinical-stage Swiss biotech company focused on developing a new class of immune tolerance therapies for autoimmune disease. Before that, she was Senior Vice President of Corporate Strategy at Dimension Therapeutics, where she led Dimension’s initial public offering and subsequent acquisition by Ultragenyx in 2017. 

Her earlier roles include co-founder and Vice President of Project and Portfolio Development at Cydan Development and leadership positions at Aileron Therapeutics as Head of Portfolio Advancement and Infinity Pharmaceuticals as Director of New Product Marketing. 

Stefan Larson, Ph.D.

Larson is a Venture Partner at Sectoral Asset Management and serves on several biotech boards, including Prilenia Therapeutics, Apnimed, and Stratus Therapeutics. He previously was an Entrepreneur-in-Residence and later Venture Partner at Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and served as the founding CEO of Northern Biologics. 

Larson also co-founded two medical device companies, Perimeter Medical Imaging and Tornado Spectral Systems, and began his career at McKinsey & Company. 

Ingmar Bruns, M.D., Ph.D.

Bruns is a physician-scientist with two decades of hematology and oncology expertise who currently serves as Chief Medical Officer of Zentalis. 

He previously served as Chief Medical Officer of Trillium Therapeutics through its acquisition by Pfizer, then held senior clinical development roles at Pfizer, including head of the hematologic malignancies franchise. 

Earlier positions include Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals and clinical development leadership at Bayer Pharmaceuticals. Bruns also served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf and Albert Einstein College of Medicine.

Dion Madsen, outgoing Chair and continuing Board Member of Radiant Biotherapeutics, noted: “We are thrilled to welcome Stefan and Ingmar to our board of directors as we move towards the clinic with our lead program. The addition of Dr. Larson and Dr. Bruns brings relevant expertise necessary for us to successfully deliver our next-generation biologics to patients with cancer and autoimmune diseases. We appreciate Arthur Fratamico’s leadership and foundational contributions to the Company during his four-year tenure as CEO.”